Plain-English translation of NCT06367283 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether , an affordable medication that has been safely used for decades to treat diabetes, might also help relieve pain and improve function in people with hand osteoarthritis. Researchers want to compare how well this medication works compared to a placebo (a pill with no active ingredient) over 16 weeks. This is a Phase 3 trial, which means the medication has already shown promise in earlier studies.
Hand osteoarthritis affects millions of people and causes joint pain, stiffness, and reduced function in daily activities like gripping or typing. Currently, treatment options are limited, so researchers are exploring whether this medication—which has shown potential in early research—could offer a new, accessible way to help manage symptoms.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will be randomly assigned to take either or a placebo pill once daily for 16 weeks. You will need to visit the research clinic for assessments where researchers will measure your pain levels, hand function, and overall symptoms. Throughout the study, you'll keep track of how you're feeling and report back to the research team.
AI-generated summary from trial data · Jun 21, 2026 · Not medical advice
Denmark
Phase
Large-scale testing
Sponsor
Marius Henriksen
Enrollment target
~150 participants
Started
June 2024
Primary completion
December 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in February 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Kasper Staberg Madsen
Marius Henriksen
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.